Meet the 9 Bay Area biotechs VCs say are poised to take off

Hello,

Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and today in healthcare news:

• Meet the 9 Bay Area biotechs VCs say are poised to take off';
• Inside the psychedelics company that biotech investors are betting big on;
• What to know about past COVID-19 infections and your immunity.

If you're new to this newsletter, sign up here. Comments, tips? Email me at lramsey@insider.com or tweet @lydiaramsey125. Let's get to it...

9 top Bay Area biotechs that VCs say are poised to take off in the next year

• Insider asked top venture capitalists to name biotech startups poised to take off in the next year.
• Here are the nine startups they named that are in and around San Francisco.
• They're developing novel cancer treatments and pioneering ways to discover and manufacture medicines.

Read the full list>>

Meet the under-the-radar psychedelics company that drew big bets from some of biotech's top investors and rocketed to a $1 billion valuation

• GH Research is a psychedelics company that recently listed on the Nasdaq.
• Despite its big market value and experienced investors, not much is known about the firm.
• GH Research wants to come up with new options for treatment-resistant depression.

Check it out>>

How to think about your immunity if you're one of the nearly 39 million Americans who've had COVID-19

• A coronavirus infection doesn't guarantee long-term immunity.
• Experts advise people who've had COVID-19 to get vaccinated.
• Still, natural immunity seems to provide stronger, more lasting protection than vaccines alone.

What you need to know>>

More stories we're reading:

• Most US companies surveyed said they're planning to require employees to get vaccinated by the end of the year (Insider)
• Apple is planning to put blood-pressure measuring tools and a thermometer in its watch (The Wall Street Journal)
• At least 6 conservative radio hosts and anti-mask advocates have died from COVID-19 after bashing the vaccines (Insider)
• Novartis and the UK have reached an agreement to cover the cholesterol drug Leqvio (FiercePharma)

- Lydia